A serum/plasma exosomal miRNA marker associated with atrial septal congenital heart disease and its application

A congenital heart disease, exosome technology, applied in the field of biotechnology and diagnosis, can solve the problem of atrial septal congenital heart disease specific miRNA research that cannot be used as a marker for specific diagnosis of atrial septal congenital heart disease Few, can not be used as a wide range of screening and other issues, to achieve the effect of high reverse transcription efficiency, high sensitivity, strong accuracy

Active Publication Date: 2021-10-08
NANJING CHILDRENS HOSPITAL
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Two-dimensional color Doppler ultrasonography can describe the defect location, size and blood flow direction. Although the accuracy is high, the cost is high and it cannot be used as a method for extensive screening
[0007] However, so far, most of the relevant miRNA studies have been devoted to the general direction of congenital heart disease, including ventricular septal congenital heart disease, atrial septal congenital heart disease, patent ductus arteriosus and tetralogy of Fallot, atrial septal congenital heart disease, and atrial septal congenital heart disease. Specific miRNAs in compartmental congenital heart disease are poorly studied
Therefore, the current congenital heart disease-related miRNAs have low specificity in the diagnosis of atrial septal congenital heart disease, which increases the false positive of diagnosis and cannot be used as a marker for the specific diagnosis of atrial septal congenital heart disease.
There are few reports on the application of exosome-related miRNAs as molecular markers in the diagnosis of atrial septal congenital heart disease, and none of the existing diagnostic markers for atrial septal congenital heart disease is specific to the characteristics of exosomal miRNA expression changes in the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A serum/plasma exosomal miRNA marker associated with atrial septal congenital heart disease and its application
  • A serum/plasma exosomal miRNA marker associated with atrial septal congenital heart disease and its application
  • A serum/plasma exosomal miRNA marker associated with atrial septal congenital heart disease and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] 1. Experimental materials and methods

[0042] 1.1 Case selection

[0043] 1.1.1 Diagnostic criteria

[0044] Diagnosis of atrial septal congenital heart disease Children with simple atrial septal congenital heart disease diagnosed by echocardiography in the hospital.

[0045] 1.2 Case information

[0046] From December 2015 to December 2017, a total of 30 patients with atrial septal congenital heart disease who met the inclusion criteria were collected in this study. All cases came from the Department of Cardiothoracic Surgery of Nanjing Children's Hospital and were confirmed by pathological examination. The age of the patients ranged from 1 to 13 years, with a median age of 2.5 years. The normal control group ("normal" in this study refers to non-cardiac developmental malformations) 29 cases, aged 1-11 years, with a median age of 4 years, were healthy volunteers from the Department of Pediatrics, Nanjing Children's Hospital Affiliated to Nanjing Medical University....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a serum / plasma exosome miRNA marker related to atrial septal congenital heart disease. The application of the product in heart disease can alleviate the technical problem of insufficient research on specific miRNA related to atrial septal congenital heart disease existing in the prior art.

Description

technical field [0001] The present invention relates to the fields of biotechnology and diagnosis, more specifically, to a serum / plasma exosome miRNA marker related to atrial septal congenital heart disease and its application. Background technique [0002] Atrial septal congenital heart disease is one of the common congenital heart malformations, which is caused by the abnormality of the original atrial septum during embryonic development, resulting in a gap left between the left and right atrium. ASD can occur alone or coexist with other types of cardiovascular malformations. Congenital heart disease accounts for approximately 0.8-1.2% of birth defects. At present, there are about 2 million congenital heart disease patients in my country, and the overall incidence rate is about 8‰, and about 120,000 to 200,000 children with congenital heart disease are born every year. In the United States, there are about 8-10 children with congenital heart disease per 1000 live births,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6883C12N15/11
CPCC12Q1/6883C12Q2600/158C12Q2600/178
Inventor 莫绪明徐诚马思雨束亚琴
Owner NANJING CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products